Cognito Therapeutics

Cognito Therapeutics' Mission

Cognito Therapeutics is dedicated to developing novel therapeutics aimed at improving the lives of patients suffering from neurodegenerative diseases. Their primary focus is on creating non-invasive interventions that leverage proprietary visual and auditory stimulation to preserve brain structure and function. By targeting the cognitive and functional symptoms associated with conditions like Alzheimer's disease, Cognito Therapeutics aims to offer innovative solutions that enhance patient quality of life.

Cognito Therapeutics' FDA Breakthrough Device Designation

Cognito Therapeutics has received the FDA Breakthrough Device Designation for its treatment targeting cognitive and functional symptoms of Alzheimer’s disease. This designation is significant as it expedites the development and review of medical devices that provide more effective treatments for life-threatening or irreversibly debilitating diseases. Cognito's non-invasive therapeutic intervention, which evokes gamma wave activity in the brain, has shown promising results in clinical trials, positioning the company at the forefront of Alzheimer’s disease treatment innovation.

Cognito Therapeutics' Clinical Trial Success

Cognito Therapeutics has successfully completed Phase 2 clinical trials, demonstrating a 69% slowing of brain volume loss and a 77% slowing of functional decline in patients. These results underscore the potential efficacy of their non-invasive therapeutic intervention. The treatment, which involves visual and auditory stimulation tailored to each patient, has undergone extensive testing, with over 40,000 treatment sessions completed across multiple studies. Remarkably, no serious treatment-limiting adverse events were reported, highlighting the safety and tolerability of the intervention.

Cognito Therapeutics' Non-Invasive Therapeutic Intervention

Cognito Therapeutics has developed a non-invasive therapeutic intervention designed to evoke gamma wave activity in the brain. This innovative treatment involves a wearable device that delivers proprietary visual and auditory stimulation for one hour daily, allowing patients to receive therapy from the comfort of their homes. The light and sound intensity of the treatment are customized based on the patient's tolerability and response, as observed through EEG evaluations. By preserving brain structure and function, this intervention aims to slow the progression of neurodegenerative diseases and improve patient outcomes.

Cognito Therapeutics' Research and Development

Cognito Therapeutics is actively exploring the application of their proprietary visual and auditory stimulation treatment across multiple neurodegenerative diseases. Their research and development efforts are focused on understanding the broader implications of gamma wave activity in the brain and how it can be harnessed to combat various cognitive and functional impairments. By conducting extensive clinical studies and tailoring treatments to individual patient needs, Cognito Therapeutics is committed to advancing the field of neurodegenerative disease therapy and offering new hope to patients and their families.